A cDNA library prepared from human placenta has been screened for sequences coding for factor XIIIa, the enzymatically active subunit of the factor Xm complex that stabilizes blood clots through crosslinking of fibrin molecules. Two oligonucleotides, based on the amino acid sequences of tryptic peptides of factor XMa, were used as hybridization probes. Of 0.36 x 106 independent recombinants, 1 clone was identified that hybridized to both probes. The insert of 1704 base pairs coded for the amino-terminal 541 amino acid residues of the mature factor XIIIa molecule. Blot-hybridization analysis using this cDNA as a probe showed that the factor XIIIa mRNA from placenta has a size of approximately 4000 bases. The insert was used to rescreen cDNA libraries and to identify further factor XMa-specific. sequences. The total length of the isolated factor XILIa cDNA is 3905 bases, and it codes for a protein of 732 amino acids. In spite of the presence of factor XIII in blood plasma, we could not identify a leader sequence typical for secreted proteins.
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Factor XIII (FXIII) is a blood coagulation protein that is distributed both extracellularly (in plasma) and intracellularly (in megakaryocytes and platelets) (1, 2) . In placenta the exact cellular location of FXIII is not known. Data obtained by indirect immunofluorescence suggest, however, that enzymatically active FXIII is located both intracellulary and extracellulary in the stroma of placental villi (3) . FXIII is the last zymogen to become activated in the coagulation cascade during the blood-clotting process of vertebrates (4) . FXIII molecules from blood platelets and megakaryocytes and from placental tissue are indistinguishable by several criteria and are each dimers composed of two identical a subunits (a2) with a monomeric molecular weight of about 80,000 (3) . Blood plasma FXIII, on the other hand, is a tetramer (a2b2) of molecular weight 300,000-350,000. It contains two noncatalytic b subunits (Mr 90,000) in addition to its two catalytic a subunits, which are believed to be identical to those of platelet, megakaryocyte, and placental origin (3) . Upon activation by thrombin and in the presence of Ca2+, the plasma-derived FXIII dissociates its noncatalytic b subunits and yields the same active enzyme, FXIIIa*, as zymogens derived from megakaryocytes, platelets, or placenta. The enzymatic active form of FXIII, the FXIIIa* [also called activated fibrin-stabilizing factor, fibrinoligase, or plasma transglutaminase, EC 2.3.2.13 (protein-glutamine:amine yglutamyltransferase)] contains a cysteine in its active center and acts as a transglutaminase in the blood coagulation process. It catalyzes the formation of a -glutamyl-e-lysyl bond between fibrin molecules (5), fibrin and a2-plasmin inhibitor (6) , fibronectin molecules (7), fibronectin and fibrin (7) , and fibronectin and collagen (8) during the formation of an insoluble clot. The formation of covalent crosslinks by FXIII is important not only for normal blood coagulation but also for wound healing and placental retention (3) .
Normal concentrations of FXIII in plasma are 10-20 mg/liter (9) . Deficiency of FXIII results in inefficient wound and bone healing, and women with FXIII deficiency have a high risk of early abortions. The hereditary deficiency of FXIII is rare, with a frequency of 1 in 2 x 106 (10). Hereditary and acquired FXIII deficiencies are treated by substitution therapy.
Inherited deficiency of FXIII usually results from a failure to produce active subunit a or from the production of functionally abnormal forms (11, 12) . Family studies of genetic variants ofboth a and b subunits have established that the structural loci for the two subunits are on different autosomes (13, 14) . Moreover, it has been reported recently that the gene for the a subunit is distal to HLA on chromosome 6 (15) .
The activation of FXIII is a multistep process involving (0) thrombin cleavage of the bond between Arg-37 and Gly-38 and release of the NH2-terminal 37-residue peptide (16) , (it) a conformational change induced by calcium ions, and (iii) in the case of the plasma zymogen, weakening of the strong noncovalent interaction between subunits a and b (17) .
Prior Isolation of RNA and Preparation of cDNA Libraries. RNA was prepared from a mature human placenta by the standard guanidinium thiocyanate extraction procedure (19) . Poly(A)+ RNA was selected by oligo(dT)-cellulose chromatography (20) . Poly(A)+ RNA (=4 ttg) was copied into cDNA with reverse transcriptase, and double-stranded cDNA was prepared by the method of Gubler and Hoffman (21) . After treatment with T4 polymerase, the cDNA was methylated with EcoRI methylase and ligated to EcoRI linkers. The products were cleaved with EcoRI and separated in a 5-20% . We chose the sequence Met-MetAsp-Ile-Thr-Asp-Thr for the synthesis of a "short" 20-mer, degenerated probe with the sequence: ATG ATG GAY ATH ACN GAY AC, in which Y = T or C, H = T or A or C, and N = T or A or C or G. In addition, a "long" 66-mer, undegenerated probe was constructed according to the rules of Lathe (22) by using the following strategy. First, two overlapping oligonucleotides corresponding to the sequences Tyr-Gly-Gln-Phe-Glu-Asp-Gly-Ile-Leu-Asp-Thr-Cys-Leu and Asp-Thr-Cys-Leu-Tyr-Val-Met-Asp-Arg-Ala-Gln-MetAsp were synthesized. (25) . Overlaps were specified by Southern blot analysis (26) and sequence analysis. Nucleotide acid sequence was determined by the chemical method of Maxam and Gilbert (27) as well as by the dideoxy method of Sanger (28) . DNA sequence data were analyzed by University of Minnesota Apple II sequence analysis programs.
RESULTS
Isolation ofHuman FXIIIa cDNA. The amino acid sequence of human placental FXIIIa has been determined by classical methods involving Edman degradation (29) . From the available data (N. Takahashi Fig. 3) . A 66-mer unique probe was constructed according to rules published by Lathe (22) , and a 20-mer was synthesized that was 48-fold degenerate.
Clear plaques (3.6 x 105) of the human placenta cDNA library were screened with either the 20-mer or the 66-mer oligonucleotide as probe. Seven plaques hybridized to either one of the probes, but only one (XgtlO-12) hybridized specifically when rescreened with both probes.
Phage DNA from this positive plaque was isolated, digested with EcoRI, and analyzed by Southern blotting with the same two probes. The analysis resulted in a large (1161 bp) EcoRI fragment hybridizing to the 66-mer probe and a small (543 bp) EcoRI fragment hybridizing to the 20-mer probe. As the 66-mer unique probe was constructed from partially complementary 39-mer oligonucleotides A and B, the XgtlO-12 insert was also probed with A and B separately. Both 39-mer probes hybridized specifically to the large 1161-bp fragment, which was another strong indication that the cDNA insert indeed carries FXIIIa-specific sequences; this subsequently was confirmed by DNA sequencing.
The 1704-bp insert of XgtlO-12 was used to screen the total cDNA library of 1 x 106 clear plaques for further FXIIIaspecific sequences. A total of 16 recombinants showed positive signals and were further characterized. Four of the positive signals showed DNA inserts located at the 5' end of the XgtlO-12 insert, but none of them were found to extend more than six bases from the 5' end of the XgtlO-12 insert sequence. Several cDNA inserts were identified from the 3' end of the FXIIIa coding sequence, of which only the insert of XgtlO-11 extends more than 2 kilobases (kb) beyond XgtlO-12, the overlap between both inserts being 237 bp. Nucleotide analysis showed that this clone specifies the 3' end of the FXIIIa mRNA.
Attempts using the primer extension approach to obtain clones from the 5' end of the mRNA that extend further upstream into the nontranslated region were without success.
IdentfWication of FXMa-Specific mRNA. The size of mRNA coding for FXIIIa was determined for poly(A)+ RNA from human placenta and liver by electrophoresis through gels containing formaldehyde and by subsequent blot-hybridization analysis with the 1704-bp insert of XgtlO-12 as a hybridization probe. One mRNA species of about 4 kb hybridized to the FXIIIa cDNA probe. This size of the FXIIIa mRNA agrees well with the size of the mRNA deduced from isolated cDNA inserts shown in Fig. 1 . Only the placental poly(A)+ RNA showed a signal, while no such signal could be detected in the case ofliver poly(A)+ RNA (Fig. 2) (30) and thus could represent a ribosome binding site:
The stop codon UGA is followed by about 1.6 kb of noncoding region, which ends in a poly(A) tail of 89 residues. At the 3' end of the mRNA, the putative poly(A) addition signal AATAAA is located 15 nucleotides upstream of the beginning of the poly(A) tail. The codon usage for the FXIIIa mRNA is in good agreement with the data for eukaryotic proteins presented by Lathe (22) . In fact, the 66-mer that was used as a hybridization probe shows differences in only seven positions to the actual sequence (Materials and Methods and Fig. 3) .
From the deduced amino acid sequence, the mature (16, 29, 31) . This is in agreement with an analysis of 1764 eukaryotic protein sequences that showed that serine, alanine, or glycine in the second position favor removal ofthe initiator methionine and N-acetylation of the NH2-terminal amino acid (32) . Fourth, the third base preceding the codon for the first methionine is an adenine, which is typical for the initiation of translation in eukaryotes (33, 34) . Fifth, 41 nucleotides upstream from the initiation codon appears a putative ribosome-binding consensus sequence CCTCTG, which is frequently found in eukaryotic mRNAs (35 (Fig. 3) bridge, with four of the cysteines being in the free SH form (29) . The fact that most cysteine residues are in a reduced form can also be taken as an indication for the intracellular biological role of FXIIIa.
Blot-hybridization analysis of poly(A)+ RNA from placental tissue showed a mRNA for FXIIIa that is about 4000 bases in length. This is in good agreement with the length of the cloned cDNA sequence of 3905 bases. Thus, the FXIIIa mRNA carries 2196 bases of protein coding sequence, 1625 bases of 3' noncoding sequence, and at least 84 bases of 5' noncoding sequence. The unusually long 3' noncoding sequence carries several open reading frames. Three of them, starting with a methionine, have potential coding capacities for >50 amino acids. The longest could code for a peptide of 67 amino acids (nucleotides 2691-2891), and the others, for peptides of 55 (nucleotides 3348-3512) and 54 (nucleotides 3317-3478) residues, respectively. Whether these open reading frames have any biological significance remains to be shown.
Comparison of blot-hybridization analysis of poly(A)+ RNA from mature placenta and from liver showed that FXIIIa mRNA concentration is at least 20 times higher in placenta compared to liver. Up to now the liver was considered to be the major place for FXIIIa synthesis. The normal concentration of FXIIIa in plasma is about 10-20 mg/liter, while about 30 mg are extracted from a mature placenta (36) . The concentrations of FXIIIa during placental development have not yet been reported in the literature, but FXIIIa might be specifically induced at the late stage of placental development where stabilization of blood clots is of high importance. In that respect it is noteworthy that the other examples of secreted proteins that do not carry a leader peptide are induced by hormones: ovalbumin and lipocortin (37, 38) . In both cases the NH2-terminal amino acid ofthe mature protein molecules (glycine and alanine, respectively) is acetylated.
The cloning of FXIIIa cDNA now enables questions to be answered regarding the glycosylation pattern and the mechanism of secretion by introducing the coding sequence into different host cells.
